The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism (VTE), dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.
The CLOT study, published in 2003, demonstrated the effectiveness of dalteparin in preventing further blood clots in individuals with cancer and acute deep vein thrombosis.